Third-generation aromatase inhibitors (AI) are already well established as the fi rst-line treatment of advanced stage breast cancer. However, new data is emerging showing AIs to be a possible alternative to tamoxifen in early stage breast cancer. Dr Andrew Wardley reviews the role of AIs as a neoadjuvant, adjuvant or an extended adjuvant in this type of breast cancer.